eprintid: 10145256
rev_number: 29
eprint_status: archive
userid: 699
dir: disk0/10/14/52/56
datestamp: 2022-03-18 10:46:19
lastmod: 2023-01-10 15:24:21
status_changed: 2023-01-10 15:24:21
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Bermingham, Charlotte
creators_name: Morgan, Jasper
creators_name: Ayoubkhani, Daniel
creators_name: Glickman, Myer
creators_name: Islan, Hazrul
creators_name: Sheikh, Aziz
creators_name: Sterne, Jonathan
creators_name: Walker, Ann
creators_name: Nafilyan, Vahe
title: Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in England: a quasi-experimental study
ispublished: pub
divisions: UCL
divisions: J38
divisions: D65
divisions: B02
note: © 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
abstract: Several studies reported hematological abnormalities after vaccination against the coronavirus disease 2019 (COVID-19). We evaluated the association between COVID-19 vaccines (CoronaVac and BNT162b2) and hematological abnormalities. We conducted nested case–control and self-controlled case series analyses using the data from the Hong Kong Hospital Authority and the Department of Health, HKSAR. Outcomes of interest were thrombocytopenia, leukopenia, and neutropenia. Adjusted odds ratios (aORs), incidence rate ratios (IRRs), and 95% confidence intervals (CIs) were estimated using conditional logistic regression. In total, 1 643 419 people received COVID-19 vaccination (738 609 CoronaVac; 904 810 BNT162b2). We identified 457 and 422 cases after CoronaVac and BNT162b2 vaccination, respectively. For CoronaVac, the incidence of thrombocytopenia, leukopenia, and neutropenia was 2.51, 1.08, and 0.15 per 10 000 doses. For BNT162b2, the corresponding incidence was 1.39, 1.17, and 0.26 per 10 000 doses. The incidence per 10 000 COVID-19 cases were 1254, 2341, and 884, respectively. We only observed an increased risk of leukopenia following the second dose of BNT162b2 (aOR 1.58, 95% CI 1.24–2.02; day 0–14, IRR 2.21; 95% CI 1.59–3.08). There was no increased risk of any hematological abnormalities after CoronaVac vaccination. We observed an increased risk of leukopenia shortly after the second dose of BNT162b2. However, the incidence was much lower than the incidence following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. There was no association between CoronaVac and hematological abnormalities. The benefits of vaccination against COVID-19 still outweigh the risk of hematological abnormalities.
date: 2022-04
date_type: published
publisher: Oxford University Press (OUP)
official_url: https://doi.org/10.1002/ajh.26478
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1945017
doi: 10.1002/ajh.26478
lyricists_name: Walker, Ann
lyricists_id: ASWAL40
actors_name: Walker, Ann
actors_id: ASWAL40
actors_role: owner
full_text_status: public
publication: American Journal of Epidemiology
volume: 97
number: 4
pagerange: 470-480
citation:        Bermingham, Charlotte;    Morgan, Jasper;    Ayoubkhani, Daniel;    Glickman, Myer;    Islan, Hazrul;    Sheikh, Aziz;    Sterne, Jonathan;         ... Nafilyan, Vahe; + view all <#>        Bermingham, Charlotte;  Morgan, Jasper;  Ayoubkhani, Daniel;  Glickman, Myer;  Islan, Hazrul;  Sheikh, Aziz;  Sterne, Jonathan;  Walker, Ann;  Nafilyan, Vahe;   - view fewer <#>    (2022)    Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in England: a quasi-experimental study.                   American Journal of Epidemiology , 97  (4)   pp. 470-480.    10.1002/ajh.26478 <https://doi.org/10.1002/ajh.26478>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10145256/17/Walker_American%20J%20Hematol%20-%202022%20-%20Sing%20-%20COVID%E2%80%9019%20vaccines%20and%20risks%20of%20hematological%20abnormalities%20%20Nested%20case%20control%20and.pdf